OpenSourceMalaria:Other GSK Series Under Consideration: Difference between revisions
Line 8: | Line 8: | ||
[[Image:TCMDC137322.png|thumb|center|540px|Scheme 1: TCMDC 137332]] <br> | [[Image:TCMDC137322.png|thumb|center|540px|Scheme 1: TCMDC 137332]] <br> | ||
InChI=1S/C17H18ClNO2/c1-17(2,3)16(20)19-14-6-4-5-7-15(14)21-13-10-8-12(18)9-11-13/h4-11H,1-3H3,(H,19,20) | |||
ClC(C=C1)=CC=C1OC2=CC=CC=C2NC(C(C)(C)C)=O | |||
Citations for exact structure search: | Citations for exact structure search: | ||
Line 20: | Line 22: | ||
ComGenex Compound (Scheme 2) | ComGenex Compound (Scheme 2) | ||
[[Image:ComGenex.png|thumb|center|540px|Scheme 2: ComGenex Compound]] <br> | [[Image:ComGenex.png|thumb|center|540px|Scheme 2: ComGenex Compound]] <br> | ||
InChI=1S/C17H17Cl2NO2/c1-17(2,3)16(21)20-13-6-4-5-7-15(13)22-14-9-8-11(18)10-12(14)19/h4-10H,1-3H3,(H,20,21) | |||
ClC(C=C1)=CC(Cl)=C1OC2=CC=CC=C2NC(C(C)(C)C)=O |
Revision as of 17:51, 12 May 2013
Other GSK Series Under Consideration
The team have focused on the synthesis and evaluation of two series (the aryl pyrroles and aminothienopyrimidines) to date. The focus of the project could change quite rapidly following the receipt of new biological data (for highly active or inactive compounds). This page highlights other GSK compounds from the TCAMS data that look attractive.
TCMDC 137332
InChI=1S/C17H18ClNO2/c1-17(2,3)16(20)19-14-6-4-5-7-15(14)21-13-10-8-12(18)9-11-13/h4-11H,1-3H3,(H,19,20) ClC(C=C1)=CC=C1OC2=CC=CC=C2NC(C(C)(C)C)=O
Citations for exact structure search: DOI:10.1021/ml200135p – GSK Paper on Open Innovation WO 1994-GB1409 – Preparation of anti-atherosclerotic1diaryl compound, The Wellcome Foundation
InChi Search: No hits on Google
Citations for sub-structure search: WO 2000-EP1224 – Preparation of phenyl and pyridinyl derivatives as NK-1 receptor antagonists, 2 F. Hoffmann La Roche ComGenex Compound (Scheme 2)
InChI=1S/C17H17Cl2NO2/c1-17(2,3)16(21)20-13-6-4-5-7-15(13)22-14-9-8-11(18)10-12(14)19/h4-10H,1-3H3,(H,20,21) ClC(C=C1)=CC(Cl)=C1OC2=CC=CC=C2NC(C(C)(C)C)=O